Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Here’s to why InspireMD Inc. (NSPR) stock surges during current market trading?

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

InspireMD Inc. (NASDAQ: NSPR) stock gains by 6.63% during the current market trading session. InspireMD wants to use its patented MicroNet technology to produce such products which are of industry standard for cartoid stenting by delivering excellent short-term results and long-term outcomes that are free of stroke.

NSPR stock’ Current Development

The National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) has given InspireMD’s CGuard EPS stent system a favourable opinion on reimbursement in France. From October 25, 2021, the CGuard EPS will be included in the list of reimbursed medical goods (LPPR). Considering CNEDIMTS’ favourable opinion for reimbursement on May 11, 2021, for the treatment of symptomatic and non-symptomatic lesions where surgery is not needed, this was the penultimate step for full commercial introduction of CGuard EPS.

The CGuard EPS Self-Expanding Carotid Stent is a new open-cell nitinol self-expanding stent with proprietary MicroNet mesh technology that decrease the chance of early and late embolism.

Marvin Slosman, CEO of InspireMD commented,

CGuard EPS is now available for use in the treatment of carotid artery disease and stroke control in France, due to this achievement. By shifting away from surgical endarterectomy and more towards less invasive alternatives like the CGuard EPS Carotid Stent System, they want to enhance the level of care in the management of carotid artery disease. This technology, they think, is the most sophisticated and safest stent system available today due to its unique and patented design.

Andrea Tommasoli, Senior VP Global Sales and Marketing stated,

They worked with HAS for almost a year to get reimbursement clearance, and its assessment verified the efficacy and safety of using the CGuard EPS carotid stent, based on their unrivalled and growing portfolio of clinical data and the findings of their large clinical research programme. As they strive to develop CGuard as the carotid device of choice among physicians treating carotid disease across the world, the introduction of CGuard into France is another step forward in their efforts to expand the global reach of their commercial products.

Leave a Comment

Your email address will not be published. Required fields are marked *

Latest Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam